Home › NCT05864274

Improve Cancer-related Cognitive Impairment

Using a Novel Mobile Cognitive Training Application to Improve Cancer-related Cognitive Impairment in Gynecologic Oncology Patients

Who can join

Ages 18 to 90 · Women · Healthy volunteers welcome

Inclusion criteria are:

* newly diagnosed gynecologic malignancy (uterine, cervical, ovarian, primary peritoneal, vulvar, or vaginal) and undergoing chemotherapy
* own a smartphone or tablet with ability to download cognitive training application
* and age \>21 years old

Exclusion criteria include:

* medical diagnosis of dementia
* significant underlying mental diagnoses for which they are on more than 1 medication for (patients with depression or anxiety on single-agent therapy will be able to participate
* age \<21

About the study

Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments. This application focuses on evaluating if using a cognitive mobile training application can decrease the impact of CRCI in gynecologic oncology patients through a multidisciplinary approach with patients undergoing assessments by our neurocognitive team.

What is being tested

• Cognitive training application (device)

Sponsor: University of Alabama at Birmingham · Participants: 64 · Started: Sep 1, 2024

Contact the study team

• Teresa K Boitano, MD · Phone: 2059344986

Official record on ClinicalTrials.gov — NCT05864274

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.